Isorhamnetin for COVID-19
Isorhamnetin has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Computational investigation on the antioxidant activities and on the Mpro SARS-CoV-2 non-covalent inhibition of isorhamnetin, Frontiers in Chemistry, doi:10.3389/fchem.2023.1122880 ,
Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules, ACS Omega, doi:10.1021/acsomega.2c05766 ,
Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review, Inflammation Research, doi:10.1007/s00011-022-01642-7 ,
In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library, Pharmaceuticals, doi:10.3390/ph15030308 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.